Dec 24- Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan. Actavis did not give any further details on the contents of the letter. In a study, the drug combination was found more effective in reducing blood pressure in patients of hypertension,...» Read More
I'm blogging today from outside the New York Stock Exchange where I'm trying to round up "man-on-the-(Wall) street" reaction to the markets. In the meantime, back on the beat, for the second day Merck and Schering-Plough have taken out two-page ads in major newspapers defending their cholesterol drugs Zetia and Vytorin whose efficacy is under attack.
Roche Holding has overcome Ventana's resistance to its takeover bid by raising its price, acquiring the diagnostics maker for $3.4 billion to boost its cancer testing business.
I blogged recently that a spokesperson for the House Energy and Commerce Committee had told me a decision could be made by the end of this week regarding the Dendreon saga.
After watching his stock lose more than one-fifth of its value this week, Schering-Plough CEO Fred Hassan apparently decided the shares are on sale. This morning the company issued a press release announcing Hassan (pronounced Haa-sun, not the commonly mispronounced Huh-sahn) will shell out $2 million of his own money to buy SGP shares on the open market.
This doesn't come as any big surprise, but Pfizer announced this morning that it is putting a warning--and that's the company's word--on the label of its stop-smoking pill Chantix. It says people taking the drug should be watched for "serious neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior."
Playing defense is the best thing to do right now, Jeff says. Don't pick a bottom yet.
Europe's major indexes closed lower across the board Thursday despite assurances from Federal Reserve Chairman Ben Bernanke that he would act agressively to counter the risks of a U.S. recession.
If or when you watch one of the presidential debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...
The American College of Cardiology is weighing in on the controversial ENHANCE study that has battered shares of Merck and Schering-Plough over the past couple of days. Most notably I think is that the ACC says, "There should be no reason for patients to panic."
The European Commission raided some of the world's largest drugmakers on Wednesday, launching a broad investigation into whether they made illegal deals or abused patents to limit competition and harm consumers.
It's a booyah-free zone. There goes Swifty!Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
To politicians, railing against it brings votes. To companies, it cuts costs. But to Cramer, it’s a chance to make Homegamers some mad money.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Big pharma is heralded for inventing new cures, but the courts are clogged with dangerous drug cases. Most of the world has used plant-based remedies for hundreds if not thousands of years. Here, there's plenty of skepticism, but Chris Kilham, professor of ethnobotany and explorer in residence at the University of Massachusetts, says herbal medicines are much safer than synthetic drugs.
I had planned to blog about the nearly unanimous bearish analyst commentary this morning after Genentech's earnings report yesterday. The biotech giant beat on earnings per share, but came up short on Street expectations for sales of its top four drugs. DNA shares are under pressure again today.
In the wake of Pfizer pulling the plug on its poor-selling inhaled insulin Exubera, the world's biggest diabetes drug company, Novo Nordisk is throwing in the towel on development of its version of inhaled insulin.
Genentech reported a profit that rose 6.4 percent and beat forecasts, but sales of all four of the company's main drugs fell short of expectations.
The highly anticipated results of the study that goes by the acronym "ENHANCE" are out this morning. You can see what it stands for in the companies' press release. (I wonder how many meetings and brainstorming sessions go into coming up with some of the industry's clinical trial acronyms and abbreviations.)
Merck and Schering-Plough said a closely watched study involving its Vytorin cholesterol treatment failed to reach its main goal.
The brouhaha over the Food and Drug Administration's delay of the potential approval of the prostate cancer drug Provenge from the small biotechnology company Dendreon is now entering the prestigious and credible sphere of peer-reviewed scientific journals.